Introduction
For most of the last decade, the Drug Supply Chain Security Act (DSCSA) has been a background compliance project for pharmaceutical companies: something IT and supply chain teams were quietly implementing against a series of phased deadlines that always seemed to be a year or two away. That is no longer true. The law's enhanced drug distribution security requirements, the unit-level, package-by-package traceability system DSCSA was always building toward, are now in force, and the multi-year enforcement discretion period FDA granted while the industry caught up has ended for most of the supply chain. That shift has quietly created real regulatory affairs work, not just supply chain and IT work, and it is worth understanding what that work actually looks like.
DSCSA is easy to think of as a warehouse and data-systems problem, and much of it genuinely is. But regulatory affairs sits at the point where the law's requirements meet FDA guidance, enforcement posture, and a company's actual product portfolio, and that intersection has become a steady source of work for people who understand both the regulation and the practical realities of getting product to patients.
What DSCSA Actually Requires Now
At its core, DSCSA requires that most prescription drug packages carry a product identifier, encoding the National Drug Code, a serial number, lot number, and expiration date, and that trading partners across the supply chain, manufacturers, wholesale distributors, repackagers, and dispensers, be able to exchange that information electronically and verify it at the package level. The goal is a fully interoperable, unit-level traceability system that can identify and, when necessary, quarantine suspect or illegitimate product quickly, rather than relying on the lot-level tracing and paper pedigrees the industry used for years beforehand.
That sounds straightforward as a sentence. In practice it means every trading partner in a product's chain of custody has to be able to send, receive, and verify serialized transaction data in a standard format, generally built around EPCIS data exchange and a verification router service that lets a company confirm a product identifier against the original manufacturer's data without every party needing direct access to every other party's systems. Getting that interoperability working across an entire industry, not just within one company, is the part that took years longer than the statute originally assumed.
Why the Timeline Slipped, and Why That Matters Now
The enhanced drug distribution security requirements were originally due to take full effect in November 2023, a full decade after the law was signed. FDA recognized well before that date that large parts of the supply chain, particularly smaller dispensers and some wholesalers, were not going to be ready for full interoperable, unit-level verification, and it issued guidance extending enforcement discretion for roughly another year to give the industry more time to stabilize the systems involved. That stabilization period has since ended for most trading partners, which means the requirements that used to be aspirational are now the operating baseline FDA expects companies to meet, with inspection and enforcement attention to match.
For regulatory affairs, that transition from enforcement discretion to active expectation is the real story. A requirement that used to be answered internally with "we're working toward it, and FDA has said that's acceptable for now" is no longer a safe answer, and regulatory affairs is usually the function that has to know precisely where that line sits for a given product and trading partner relationship.
Where Regulatory Affairs Actually Fits In
Serialization and traceability implementation itself is typically owned by supply chain, quality, and IT, teams that build and run the physical serialization lines, the data repositories, and the verification infrastructure. Regulatory affairs' role is different but no less essential: tracking FDA's evolving guidance and compliance policy documents on DSCSA, translating what a given guidance update actually changes for the company's specific products and distribution model, and making sure the rest of the organization is working from a current, accurate understanding of what is legally required versus what is merely best practice.
This matters because FDA has issued DSCSA guidance in stages, addressing specific pain points such as which trading partners still have additional time, how suspect product investigations should be documented, and what constitutes an acceptable verification process, rather than one single finished rulebook. Someone has to read each new guidance document closely, compare it against the company's current compliance posture, and flag where a gap exists before an inspection or a trading partner audit finds it first.
Suspect and Illegitimate Product Investigations
One of the most regulatory-affairs-heavy pieces of DSCSA in practice is the suspect product response. When a trading partner identifies a product that may be counterfeit, diverted, stolen, intentionally adulterated, or otherwise illegitimate, DSCSA requires a documented investigation within a defined timeframe, and if the product is confirmed illegitimate, formal notification to FDA and to trading partners who may have received the same product. Regulatory affairs frequently owns or co-owns that notification process, because it requires the same judgment and precision that a health authority communication in any other context demands: describing the issue accurately, meeting the notification deadline, and keeping the company's language consistent with what quality and legal have documented internally.
This is not a hypothetical program sitting in a binder. Counterfeit and diverted product cases do occur, and a company's DSCSA investigation and notification file is exactly the kind of record an FDA inspector may ask to review to confirm the program is a living process rather than a paper exercise.
Working Across Trading Partners
DSCSA compliance is inherently a multi-party problem: a manufacturer's system has to interoperate with wholesalers, repackagers, and dispensers who are all running different platforms on different timelines. Regulatory affairs often gets pulled into trading partner agreements and audits, confirming that a partner's licensure is current, that their verification capabilities meet the statute's requirements, and that the paperwork trail supporting a transaction meets DSCSA's transaction information and transaction statement requirements. For companies that distribute through complex networks, including specialty pharmacies, 3PLs, and international distribution arrangements layered on top of DSCSA's domestic requirements, this cross-partner verification work has become a recurring, not occasional, part of the job.
New Roles and Where They Sit
Larger pharmaceutical and biotech companies have increasingly created dedicated track-and-trace or serialization compliance roles, sometimes inside regulatory affairs, sometimes inside quality or supply chain with a regulatory affairs dotted line. The title varies more than the substance: someone has to own the regulatory interpretation of DSCSA guidance, keep the internal compliance matrix current as FDA issues updates, and act as the point of contact when a trading partner or an FDA investigator has a question about the company's traceability program. People coming into regulatory affairs with any exposure to this area, even a single DSCSA project during an internship or an early role, tend to stand out, because relatively few candidates can speak to it with any real depth.
These roles also tend to sit closer to operations than a typical regulatory affairs job, with more day-to-day contact with warehouse and distribution staff, IT system owners, and external trading partners than a submissions-focused role usually involves. For someone who enjoys the regulatory side of the work but wants more variety than a pure writing-and-filing role offers, that operational exposure can be a genuine draw rather than a drawback.
How This Compares to Other Markets' Traceability Systems
The United States is not alone in building a serialized traceability system, and regulatory affairs professionals working across markets increasingly need to hold more than one framework in their heads at once. The EU's Falsified Medicines Directive established its own serialization and verification system years before DSCSA's enhanced requirements took full effect, built around a central European Medicines Verification System that pharmacies check at the point of dispensing rather than the more phased, trading-partner-by-trading-partner verification model DSCSA uses. The two systems share a common goal, keeping counterfeit and diverted product out of the legitimate supply chain, but they differ enough in mechanics, what gets scanned, when, and by whom, that a compliance approach built for one does not simply transfer to the other. Companies distributing the same product under both frameworks need regulatory affairs professionals who can keep the two sets of obligations straight and explain accurately, to internal teams and to auditors, which requirement applies where.
What This Means for a Regulatory Affairs Career
DSCSA work will not replace the core submission and labeling work most regulatory affairs careers are built on, and it should not be mistaken for a primary specialty the way CMC or labeling is. But as enforcement discretion narrows and FDA's inspection attention to traceability systems increases, being the person on a team who can read a DSCSA guidance document, translate it accurately, and keep an investigation file defensible is a genuinely useful, differentiating skill. It rewards the same qualities that serve regulatory affairs professionals everywhere: careful reading of agency guidance, comfort working across quality, IT, and legal, and the discipline to keep documentation current even when the underlying requirement feels procedural rather than urgent.
Conclusion
DSCSA spent a decade as a slow-moving implementation project most regulatory affairs professionals could reasonably ignore. That window has closed. With enhanced drug distribution security requirements now the active standard and enforcement discretion largely behind the industry, the guidance-tracking, trading-partner, and suspect-product-investigation work that sits squarely in regulatory affairs' lane has become a steady, recurring part of the job at companies of every size. It is not the most visible part of a regulatory affairs career, but it is real, it is growing, and it rewards exactly the skills the rest of the profession already values.